New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
暂无分享,去创建一个
[1] E. Van Cutsem,et al. Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: results of a large phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Buzdar,et al. Multicenter, Phase II study of capecitabine in taxane‐pretreated metastatic breast carcinoma patients , 2001, Cancer.
[3] Dan L. Longo,et al. Cancer Chemotherapy and Biotherapy: Principles and Practice , 2001 .
[4] R. Elledge,et al. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.
[5] E Harrison,et al. Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer: results of a randomized phase III study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] R. Schilsky,et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] G. Peters,et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] K. Sugimachi,et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma , 2000, British Journal of Cancer.
[9] T. Hickish,et al. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] B. Reigner,et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours , 2000, British Journal of Cancer.
[11] R. Schilsky,et al. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.
[12] H. Burger,et al. Capecitabine, an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] L. Grochow,et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] B. Reigner,et al. Preferential activation of capecitabine in tumor following oral administration to colorectal cancer patients , 2000, Cancer Chemotherapy and Pharmacology.
[15] B. Reigner,et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Buzdar,et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] B. Reigner,et al. A Phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.
[18] G. Hortobagyi,et al. Treatment of breast cancer. , 1998, The New England journal of medicine.
[19] R. Pazdur,et al. The oral fluorouracil prodrugs. , 1998, Oncology.
[20] B. Reigner,et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] C. Punt. New drugs in the treatment of colorectal carcinoma , 1998, Cancer.
[22] M. Ratain,et al. Oral chemotherapy: rationale and future directions. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] H. Ishitsuka,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.
[24] C. Punt,et al. 5-Fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. , 1998, Anti-cancer drugs.
[25] R. Schilsky,et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[26] R. Carlson. Quality of life issues in the treatment of metastatic breast cancer. , 1998, Oncology.
[27] H. Ishitsuka,et al. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. , 1998, Cancer research.
[28] P. Ravdin,et al. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Buyse,et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] K. Redmond. Assessing patients' needs and preferences in the management of advanced colorectal cancer. , 1998, British Journal of Cancer.
[31] C. Topham,et al. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer--a pilot study. , 1997, European journal of cancer care.
[32] D. Rothenbacher,et al. Treatment decisions in palliative cancer care: patients' preferences for involvement and doctors' knowledge about it. , 1997, European journal of cancer.
[33] D. Amadori,et al. Doxorubicin and paclitaxel (sequential combination) in the treatment of advanced breast cancer. , 1997, Oncology.
[34] P. Rougier,et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] M. Yin,et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] E. Warner,et al. Patient preferences for oral versus intravenous palliative chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[37] G. Hortobagyi,et al. Current management of advanced breast cancer. , 1996, Seminars in oncology.
[38] R. Pazdur,et al. Phase I trials of uracil‐tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule‐dependent toxicities , 1996, Anti-cancer drugs.
[39] M. Inbar,et al. Advanced colorectal carcinoma: redefining the role of oral ftorafur , 1996, Anti-cancer drugs.
[40] D. Haller,et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. , 1996, Journal of the National Cancer Institute.
[41] H. Bleiberg. Colorectal cancer: the challenge. , 1996, European journal of cancer.
[42] H. Schmoll. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. , 1996, European journal of cancer.
[43] F. Sanchiz,et al. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. , 1994, Japanese journal of clinical oncology.
[44] J. Ajani,et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[45] S. Payne. A study of quality of life in cancer patients receiving palliative chemotherapy. , 1992, Social science & medicine.
[46] J. Lokich,et al. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparisons. , 1992, Cancer.
[47] J G Fryer,et al. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program Study. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[48] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[49] V. Vaitkevicius,et al. Comparison of continuously infused 5‐fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma , 1975, Cancer.